Kenneth B. Lee, General Partner
Ken is co-founder of Hatteras Venture Partners II and former co-head of the International Life Science Practice at Ernst & Young; He is currently Chairman of Inspire Pharmaceuticals, and a member of the boards of OSI Pharmaceuticals, CV Therapeutics and Pozen. More...

Douglas Reed, MD, General Partner
Prior to coming to Hatteras, Doug spent thirteen years at Vector Fund and SR One. He also spent four years in business development Geltex and NPS. Doug was formerly a practicing radiologist at Yale and U. of Washington, and received his MBA from Wharton. He is a member of the boards of CGI Pharmaceuticals, Digirad, Viamet, and Phase Bioscience. More...

Clay B. Thorp, General Partner
Clay is co-founder of Hatteras Venture Partners I and II, the co-founder and CEO of Synthematix, Inc., a co-founder of Novalon, and a co-founder of Xanthon. He is currently Chairman of Pathfinder Therapeutics, a board member of Phase Bioscience and ArtusLabs, and a board observer of Respirics. More...

John Crumpler, General Partner
John is co-founder of Hatteras Venture Partners I and II. Formerly a successful software entrepreneur, he was founder and CEO of E-Comm, Inc. John also served on the Economic Development Board of the State of North Carolina. In addition to serving on the board of Clinipace, he is responsible for strategy, administration, and operations of Hatteras Venture Partners. More...

Robert Morff, PhD, Venture Partner
Bob has deep experience in medical devices and diagnostics product and business development. He is currently interim CEO of Pathfinder Therapeutics. He was CSO of the Wallace Coulter Foundation, Principal at Senmed Medical Ventures, and led research teams in Eli Lilly's Medical Device and Diagnostics Division. He has founded and led several companies in the microfluidics, stem cell, and tissue engineering areas. More...

Dana M. Fowlkes, MD PhD, Venture Partner
Dana is co-founder of Hatteras Venture Partners II; co-founder and former CEO of Novalon; co-founder of Merlin and Cadus; former medical school faculty member at UNC; board member of Karo Bio. Responsible for Hatteras investment advisory activities for HVP II; venture partner for HVP III focused on deal flow, technology evaluation, and potential interim management.

Derek Norman, PhD, Associate
Derek received his doctorate in organic chemistry from Harvard University, with a focus on the intersection between biology and chemistry. Prior to coming to Hatteras, Derek was with the management consulting firm Dean & Co., focused on proprietary trading methods.

Scientific Advisory Board
Hatteras has an outstanding scientific advisory board chaired by Herb Boyer, the founder of Genentech, and composed of leading scientists in their respective fields:

Herb Boyer, Ph.D., Co-Founder of Genentech, Professor Emeritus of Biochemistry and Biophysics, University of California, San Francisco
• James Powell, M.D., pathologist, founder of LabCorp and Tripath
• Charlie Sanders, M.D., cardiologist, former CEO of Glaxo and former Head of Massachusetts General Hospital
• Lucy Shapiro, Ph.D., Professor of Developmental Biology and Director of the Beckman Center for Molecular and Genetic Medicine, Stanford University; Co-Founder of Anacor Pharmaceuticals
• David King, CEO of LabCorp
• Arnold Levine, Ph.D., Professor of Systems Biology, Institute for Advanced Study, former President and CEO of Rockefeller University
• Beat Merz, Ph.D., medical device expert, industry and investing veteran, Investment Advisor, Trigon Medical
• Kazumi Shiosaki, Ph.D., Managing Director, MPM Capital, former SVP of Drug Discovery, Millennium Pharmaceuticals